November 2019 - Page 9 of 25

WednesdayNov 20, 2019 10:08 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Q3 2019 Results

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Tuesday announced its financial results for the quarter ended September 30, 2019. Among the highlights, Endonovo reported a 153% increase in revenues for the three months ended September 30, 2019 to $54,039 and a 293% increase in revenues for the nine months ended September 30, 2019 to $161,720, as compared to the same periods last year. “Although our third-quarter operating results and our revenues failed to meet previously announced projections, the efforts throughout the quarter and first nine-months of this year have been extremely positive considering the…

WednesdayNov 20, 2019 9:26 am

QualityStocksNewsBreaks – SinglePoint, Inc. (SING) Subsidiary Exceeds Revenue Growth Goals in Q3 2019

Direct Solar, a subsidiary of SinglePoint (OTCQB: SING), on Tuesday reported that it continues to exceed revenue growth targets and has been key to improving the company’s financials. Among other highlights, Direct Solar originated contracts totaling $4,965,975 and opened in three new states during the third quarter of 2019. “We have been on an upswing as more people are finding out about Direct Solar and what we bring to the market. From homeowners to developers and commercial building owners, we have a solution. We believe the market for residential alone is around 100 million homes. With the complexity around buying…

TuesdayNov 19, 2019 3:20 pm

QualityStocksNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) BIGtoken App Makes Owning, Monetizing Personal Data Possible

Digital-marketing and consumer-data-management technology platform company SRAX (NASDAQ: SRAX) has developed a consumer-managed data marketplace via its BIGtoken platform that enables people to own and earn from their data. An article discussing the company reads, “After being operational for a year, SRAX decided to poll its BIGtoken community regarding its data-privacy awareness. The survey yielded valuable insights into the way consumers view their online presence. For SRAX, one promising result of the survey showed that 62% of its users would allow more advertisements if they were being paid for the data that delivered the ad. Of concern for the company…

TuesdayNov 19, 2019 12:44 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development

Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer Tremendous unmet need for patient-derived tumors (PDx) for new drug development - current mouse models unreliable TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples Multi-billion-dollar market opportunity As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries…

TuesdayNov 19, 2019 12:07 pm

Quest Patent Research Corp. (QPRC) Completes Another Successful Licensing Campaign

Wholly owned subsidiary Mariner IC Inc. completes another successful licensing campaign around its Anchor Structure Portfolio Patent Licensing Revenues for the nine-months ended September 30, 2019 were approximately $2 million The company remains active in monetizing its existing portfolio as well as evaluating potential acquisitions QPRC trades on the OTCQB, offering investors an exciting opportunity to participate in the IP monetization space The Anchor Structure Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Mariner IC Inc., consists of two United States patents which relate to technology…

TuesdayNov 19, 2019 11:45 am

QualityStocksNewsBreaks – Sugarmade, Inc. (SGMD) Announces Strong Preliminary Calendar 2019 Performance that Exceeds Internal Forecasts

Sugarmade (OTCQB: SGMD), a major supplier to the hydroponic cultivation and hemp sectors, today announced preliminary calendar year-to-date revenue performance of $26 million and strengthening gross margins. Per the update, the company expects its recently-acquired hydroponics supply operation to produce approximately $32 million for the calendar year and believes it is well positioned moving into 2020 based on growing revenues and an expanding sector cost advantage. “This business sector is all about robust product sourcing, efficiency in logistics and effective e-commerce programs, not to mention effective placement on Amazon, where we are realizing great success. Our revenue and gross margin…

TuesdayNov 19, 2019 11:31 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Corporate, Scientific Milestones in NetworkNewsAudio Interview

Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, this morning announced the broadcast of a NetworkNewsAudio (“NNA”) interview with Stuart Smith of NetworkNewsWire (“NNW”). Predictive Oncology CEO Dr. Carl Schwartz joined Smith to discuss several corporate and scientific milestones that have been achieved by the company in 2019, as well as POAI’s strategy moving forward. “Predictive Oncology and its subsidiaries, in collaboration with key players in the pharmaceutical, diagnostic and biotech industries, are finding success in…

TuesdayNov 19, 2019 11:19 am

QualityStocksNewsBreaks – Wonderfilm Media Corp. (TSX.V: WNDR) (OTCQB: WDRFF) CEO Discusses Production, Talent and Expansion in Exclusive Audio Interview

Wonderfilm Media (TSX.V: WNDR) (OTCQB: WDRFF), a producer of high-quality feature films and episodic television with international appeal, today announced the broadcast of its audio interview with NetworkNewsAudio (“NNA”), a NetworkNewsWire (“NNW”) solution. In the interview, Wonderfilm Media CEO Kirk Shaw joins NNW’s Stuart Smith to discuss the company’s business model in producing quality theatrical releases and entertainment content for an expanding array of streaming services. Shaw briefly highlights Wonderfilm’s most recent releases, which include “The Fanatic,” starring John Travolta, “Tammy’s Always Dying,” starring Felicity Huffman, which premiered at the Toronto Film Festival, and action-packed thriller “Primal,” starring Nicolas Cage,…

TuesdayNov 19, 2019 11:02 am

Endonovo Therapeutics Inc. (ENDV) Offers Bright Spot in Opioid -Addiction Space with New Pain-Management Option

ENDV has developed a viable pain-control solution for those seeking alternatives to highly addictive opioids The company’s flagship product is an FDA-cleared, easy-to-place, noninvasive device that delivers pulsed electromagnetic frequencies to targeted area In one study, patients treated with Endonovo technology reported a decrease in pain medication by nearly threefold Amid mounting concern about the alarming opioid-addiction crisis, Endonovo Therapeutics Inc. (OTCQB: ENDV) offers one of the few bright spots on the horizon. Endonovo is the commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices designed to target patient pain and inflammation, a viable pain-control solution for those desperately seeking options other than highly…

TuesdayNov 19, 2019 10:59 am

QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Reports Preclinical Data Showing Positive Results for Treatment of Resistant Metastatic Lung Cancers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data at the American Association of Cancer Research Tumor Immunology and Immunotherapy Meeting 2019. According to the update, the data shows positive results for the combination of TUSC2 immunogene therapy with an anti-PD1 antibody, pembrolizumab, and for the combination of TUSC2 immunogene therapy, pembrolizumab, and chemotherapy for the treatment of some of the most resistant metastatic lung cancers, including the KRAS and LKB1 mutations. “These data not only further support existing preclinical data…

Site Search

Company Search

Month: November 2019